Gilead Sciences reports benefits of combination HIV therapy

Gilead Sciences has announced detailed 48-week data from an open-label phase III study that shows the benefits of its new combination HIV therapy.

Known as Study 109, the trial evaluated the investigational once-daily single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (E/C/F/TAF) among 1,436 virologically suppressed adult patients switching from tenofovir disoproxil fumarate-containing regimens.

The new combination therapy was able to demonstrate non-inferiority compared to the established treatment, thus meeting its primary efficacy endpoint, while it also showed statistical superiority on a number of key bone and renal laboratory parameters.

These findings will help to support Gilead's efforts to secure regulatory approval for the new treatment regimen.

Dr Norbert Bischofberger, executive vice-president for research and development and chief scientific officer at Gilead Sciences, said: "Gilead has a long history of innovation in the field of HIV, and E/C/F/TAF and the rest of the TAF-based portfolio is poised to represent the next generation of safe, simple and highly effective regimens."

This comes after a new emtricitabine/tenofovir alafenamide treatment for HIV from Gilead was accepted for European regulatory review last month.